37th Annual Winter Meeting of The Toxicology Forum

January 31-February 2, 2012 · The Fairfax at Embassy Row, Washington, DC
Keynote Lecture
Title Speaker
Keynote Address Peter Kim, Merck Research Laboratories
Session I
Title Speaker
Problem Formulation to Dose-Response: Advances via the ARA: Beyond Science and Decisions Workshops Bette Meek, University of Ottawa
Development of an Integrated Evaluation Strategy for the 21st Century: Advances via the HESI Risk21 Project John Doe, Parker Doe Partnership
Translating the Molecular Basis of Hazard to 21st Century Risk Assessment Approaches:Advances via Tox21 Project Christopher Weis, NIEHS
Improving Risk Assessment Policies and Practices to Meet the Challenges Posed by 21st Century Science Richard Becker, American Chemistry Council
EPA Framework for Human Health Risk Assessment to Inform Decision Making Julie Fitzpatrick, U.S. EPA
Session II
Title Speaker
Session II: Recent Successes and Future Challenges in Accelerating Implementation of the NRC Tox 21 Report Ed Carney, The Dow Chemical Company
Technical Challenges in Using Case Study Approaches to Accelerate Toxicity Testing in the 21st Century Mel Andersen, The Hamner Institutes
Regulatory Successes and Challenges to Accelerate Toxicity Testing in the 21st Century Vicki Dellarco, U.S. EPA
Current Applications of 21st Century Toxicology: Tiered Approaches to Predicting Toxicity George Daston, Proctor & Gamble
Global Challenges to Accelerate Toxicity Testing in the 21st Century Marty Stephens, Johns Hopkins University
Panel Discussion David Jacobson-Kram, U.S. FDA
Session III
Title Speaker
Consideration of How to Appropriately Test Immune Suppressors and Immune Modulators for Tumorigenicity Robert Johnson, Novartis
Use of a Xenograft Model as a Test Case to Demonstrate Absence of Tumor Growth Enhancement Lorrene Buckley, Eli Lilly
Considerations on a Human Cancer Risk Assessment Model for Pharmaceuticals Without the Use of Lifetime Rodent Bioassays Lutz Mueller, F. Hoffmann-La Roche Ltd
Recent Activities in the ICH Arena Regarding ICH-S1 Guidances for Carcinogenicity Testing of Pharmaceuticals Joe DeGeorge, Merck
Session IV
Title Speaker
FDA’s Perspective on the Regulatory Framework of Food Irradiation Lane Highbarger, U.S. FDA
Leafy Greens: Current Research on Microbial Control, a Case Study Chris Sommers, USDA
Industry Perspective: Consumer Acceptance and Benefits Shannon Cole, Grocery Manufacturers Association
Session V
Title Speaker
SESSION V: Threshold of Toxicological Concern: Designs, Domains, and Databases Susan Felter, Procter & Gamble Company
Workshop Introduction/Background Susan Barlow, Independent Consultant
Noncancer Endpoints Tim Adams, FEMA
Cancer Endpoints Mitchell Cheeseman, U.S. FDA
Route-to-Route Extrapolation Bob Safford, Unilever
Workshop Recommendations Ian Dewhurst, Chemical Regulation Directorate
Session VI
Title Speaker
The Use of Mode of Action Information in Risk Assessment Craig Rowlands, The Dow Chemical Company
Overview of the Hexavalent Chromium Mode of Action Research Project Laurie Haws, ToxStrategies Inc.
Using Toxicogenomics to Identify Key Events in the MOA for Oral Carcinogenicity of Cr(VI) Tim Zacharewski, Michigan State University
Using Pharmacokinetics to Improve Extrapolation of High Dose Findings in Rodents Exposed to Hexavalent Chromium in Drinking Water to Low Dose Exposures in Humans Sean Hays, Summit Toxicology, LLP.
Using MOA Information and Pharmacokinetics to Improve Quantitative Estimates of Human Cancer Risk Associated with Oral Exposures to Hexavalent Chromium Deborah Proctor, ToxStrategies Inc.
Implications of Developing an Oral Cancer Slope Factor for Hexavalent Chromium: Levels in U.S. Drinking Water David Kimbrough, Pasadena Water District
Session VII
Title Speaker
Overview of the NRC Framework David Dorman, North Carolina State University
Selecting Studies Timothy Pastoor, Syngenta
Formaldehyde Epidemiology: A Contemporary Review Philip Cole, University of Alabama at Birmingham
Weighing the Evidence for Causality Lorenz Rhomberg, Gradient Corporation
Mode of Action for Endogenous Chemicals James Swenberg, University of North Carolina
EPA’s Response to NRC Framework Vincent Cogliano, U.S. EPA
Session VIII
Title Speaker
Using a Rat MTBE PBPK Model as a Tool to Evaluate: Mode of Action and Route to Route Extrapolation Susan Borghoff, Integrated Laboratory Systems
Results of Subchronic and Chronic Studies of MTBE Administered in the Drinking Water of Wistar Rats John Moore, Hollyhouse Inc.
Update
Title Speaker
FDA’s Medical Countermeasures (MCM) Initiative: Responding Faster and More Effectively to Bioterrorism and Infectious Diseases Pamela Chamberlain, U.S. FDA
The ELSIE Database: Extractable, Leachable and Knowledge Sharing Amongst Pharmaceutical Companies and Regulators Douglas Ball, Pfizer